192 related articles for article (PubMed ID: 33566253)
1. Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.
Zhao L; Lv C; Sun L; Li Q; Wang Y; Wu M; Wang Y; Guo Z; Bian S; Kong D; Lin L; Wang Y; Zhou J; Li Y
Invest New Drugs; 2021 Aug; 39(4):961-970. PubMed ID: 33566253
[TBL] [Abstract][Full Text] [Related]
2. MYCN is a novel oncogenic target in adult B-ALL that activates the Wnt/β-catenin pathway by suppressing DKK3.
Kong D; Zhao L; Sun L; Fan S; Li H; Zhao Y; Guo Z; Lin L; Cui L; Wang K; Chen W; Zhang Y; Zhou J; Li Y
J Cell Mol Med; 2018 Jul; 22(7):3627-3637. PubMed ID: 29673070
[TBL] [Abstract][Full Text] [Related]
3. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
[TBL] [Abstract][Full Text] [Related]
4. Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia.
Kong YL; Pan BH; Liang JH; Zhu HY; Wang L; Xia Y; Wu JZ; Fan L; Li JY; Xu W
Aging (Albany NY); 2020 Aug; 12(16):16083-16098. PubMed ID: 32855355
[TBL] [Abstract][Full Text] [Related]
5. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway.
Zhou J; Zhang C; Sui X; Cao S; Tang F; Sun S; Wang S; Chen B
Invest New Drugs; 2018 Aug; 36(4):571-580. PubMed ID: 29504068
[TBL] [Abstract][Full Text] [Related]
7. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.
Guan XW; Wang HQ; Ban WW; Chang Z; Chen HZ; Jia L; Liu FT
Cell Death Dis; 2020 Jan; 11(1):20. PubMed ID: 31907371
[TBL] [Abstract][Full Text] [Related]
8. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
Zhao B; He T
Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells.
Yang S; Nan P; Li C; Lin F; Li H; Wang T; Zhou C; Zhang X; Meng X; Qian H; Wang H; Dong M
Biomed Pharmacother; 2018 Mar; 99():608-614. PubMed ID: 29710459
[TBL] [Abstract][Full Text] [Related]
10. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
Ning ZQ; Li ZB; Newman MJ; Shan S; Wang XH; Pan DS; Zhang J; Dong M; Du X; Lu XP
Cancer Chemother Pharmacol; 2012 Apr; 69(4):901-9. PubMed ID: 22080169
[TBL] [Abstract][Full Text] [Related]
11. Protein arginine methyltransferase 5 (PRMT5) activates WNT/β-catenin signalling in breast cancer cells via epigenetic silencing of DKK1 and DKK3.
Shailesh H; Siveen KS; Sif S
J Cell Mol Med; 2021 Feb; 25(3):1583-1600. PubMed ID: 33462997
[TBL] [Abstract][Full Text] [Related]
12. The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF‑κB pathway in multiple myeloma cells.
Liu Z; Jing Q; Wang Y; Li Y; Mi F; Xiang C; Fu R
Int J Mol Med; 2019 Jan; 43(1):285-293. PubMed ID: 30387821
[TBL] [Abstract][Full Text] [Related]
13. Hyper-activation of WNT/β-catenin signaling pathway mediates anti-tumor effects of histone deacetylase inhibitors in acute T lymphoblastic leukemia.
Shao N; Zou J; Li J; Chen F; Dai J; Qu X; Sun X; Ma D; Ji C
Leuk Lymphoma; 2012 Sep; 53(9):1769-78. PubMed ID: 22303878
[TBL] [Abstract][Full Text] [Related]
14. Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway.
Wang H; Liu YC; Zhu CY; Yan F; Wang MZ; Chen XS; Wang XK; Pang BX; Li YH; Liu DH; Gao CJ; Liu SJ; Dou LP
J Exp Clin Cancer Res; 2020 Dec; 39(1):278. PubMed ID: 33298132
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition and suppression of the mTOR and Wnt/β-catenin pathways in T-acute lymphoblastic leukemia by rapamycin and MYCN depletion.
Kong D; Fan S; Sun L; Chen X; Zhao Y; Zhao L; Guo Z; Li Y
Hematol Oncol; 2021 Apr; 39(2):222-230. PubMed ID: 33300153
[TBL] [Abstract][Full Text] [Related]
16. KDM1A drives hepatoblastoma progression by activating the Wnt/β-catenin pathway through inhibition of DKK3 transcription.
Ji C; Chen L; Yuan M; Xie W; Sheng X; Yin Q
Tissue Cell; 2023 Apr; 81():101989. PubMed ID: 36642006
[TBL] [Abstract][Full Text] [Related]
17. [Effect of chidamide on human B lymphoma cell lines and its mechanisms].
Li YY; Wang YF; Wang J; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):893-9. PubMed ID: 22931650
[TBL] [Abstract][Full Text] [Related]
18. Chidamide alleviates TGF-β-induced epithelial-mesenchymal transition in lung cancer cell lines.
Lin SH; Wang BY; Lin CH; Chien PJ; Wu YF; Ko JL; Chen JJ
Mol Biol Rep; 2016 Jul; 43(7):687-95. PubMed ID: 27188428
[TBL] [Abstract][Full Text] [Related]
19. Chidamide acts on the histone deacetylase-mediated miR-34a/Bcl-2 axis to regulate NB4 cell line proliferation and apoptosis.
Peng J; Li SJ; Fu X; Liu Y; Zhao XL
Kaohsiung J Med Sci; 2020 Dec; 36(12):1004-1013. PubMed ID: 32783381
[TBL] [Abstract][Full Text] [Related]
20. Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway.
Zhu M; Han Y; Gu T; Wang R; Si X; Kong D; Zhao P; Wang X; Li J; Zhai X; Yu Z; Lu H; Li J; Huang H; Qian P
Cell Rep; 2024 Apr; 43(4):114065. PubMed ID: 38578828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
